EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Janus kinase and calcineurin‐inhibitor combination in anti‐MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile

Valentine Pagis, Quentin Astouati, Lucas Pacoureau, Yann Nguyen, Pierre Bay, Antoine Roux, Laure Gallay, Vincent Cottin, Benjamin Terrier, Alain Meyer, Charles Cerf, Mathilde Neuville, Baptiste Hervier, Arthur Renaud, Benoit Suzon, Nicolas Schleinitz, Thomas Papo, Pascaline Priou, Arsène Mekinian, Audrey Ullmer, Erwan Oehler, Noémie Gensous, Alice Berezne, Luc De Saint Martin, Thierry Marhadour, Mickaël Martin, Amélie Servettaz, Maxime Samson, Laurent Gilardin, Pierre Charles, Juliette Woessner, Thierry Carmoi, Baptiste Dilly, Wladimir Mauhin, Nicolas Baillet, Sébastien Humbert, Benjamin Thoreau, Marine Lemaitre, Claire Le Pendu, Pierre Loiseau

Journal of Internal Medicine · 2026-02 · 299 (2) · 228-240

DOI: 10.1111/joim.70047 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives Anti‐MDA5 dermatomyositis (anti‐MDA5 DM) is the most severe subtype of dermatomyositis, due to its pulmonary involvement. Current treatment involves corticosteroids and immunosuppressants, but variability in responses exists. This study aims to evaluate the efficacy and safety of Janus kinase (JAK)– and calcineurin–inhibitor combination (JAK–CNI) in anti‐MDA5 DM patients. Methods A nested case–control study was conducted within a retrospective cohort of 234 anti‐MDA5 DM patients. Patients receiving JAK–CNI were matched 1:2 with comparators. All‐cause mortality or transplant within a year was compared using Cox proportional hazards models. Infectious and noninfectious side effects were also assessed. Results Twenty‐seven patients receiving JAK–CNI were compared to 52 matched controls. Almost all these patients had pulmonary involvement. Thirty‐nine (49%) died or were transplanted during follow‐up. No significant improvement in survival or transplant‐free survival was observed with JAK–CNI compared with comparators (hazard ratios 1.02, 95% confidence intervals [0.48–2.16]). Results were consistent regardless of intensive care unit (ICU) admission status and when analyses were restricted to patients with rapidly progressive interstitial lung disease. A trend toward a beneficial effect of the JAK–CNI combination was observed in non‐ICU patients. Infectious complications were frequent ( n = 49, 62%), with no excess risk in patients receiving JAK–CNI. Conclusion JAK–CNI showed a similar outcome to other immunosuppressive combinations. However, as the study included the most severe cases, the potential benefit of early JAK–CNI introduction in less severe forms cannot be dismissed, as suggested by the nonsignificant trend in non‐ICU patients. Future studies are needed to clarify the optimal timing and patient selection for JAK–CNI therapy in anti‐MDA5 DM.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →